Sign In
Last checked at 
9 May 2024 14:30
AGM Results
Dublin, London | 9 May 2024
Uniphar plc (the Company) is pleased to announce that at its Annual General Meeting held at 11.00 a.m. today, 9 May 2024, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.
Details of votes cast are set out below:
| RESOLUTION | For | For % | Against | Against % | Withheld |
1 | Financial Statements and Reports | 142,776,909 | 100 | - | 0 | 1,659,778 |
2 | Final Dividend of €3.2m | 144,436,687 | 100 | - | 0 | - |
3(a) | Re-elect Ger Rabbette | 133,691,402 | 92.56 | 10,745,283 | 7.44 | 2 |
3(b) | Re-elect Tim Dolphin | 143,757,800 | 99.53 | 678,887 | 0.47 | - |
3(c) | Re-elect Paul Hogan | 143,473,422 | 99.35 | 938,265 | 0.65 | 25,000 |
3(d) | Re-elect Sue Webb | 144,049,623 | 99.77 | 333,788 | 0.23 | 53,276 |
3(e) | Re-elect Jim Gaul | 138,288,164 | 95.78 | 6,095,247 | 4.22 | 53,276 |
3(f) | Re-elect Liz Hoctor | 144,320,340 | 99.94 | 91,347 | 0.06 | 25,000 |
3(g) | Re-elect Maurice Pratt | 141,968,268 | 98.29 | 2,468,417 | 1.71 | 2 |
3(h) | Re-elect Valerie Sick | 144,143,411 | 99.83 | 240,000 | 0.17 | 53,276 |
4 | Remuneration of Auditors | 119,304,023 | 95.49 | 5,630,519 | 4.51 | 19,502,145 |
5 | Authority to allot relevant securities | 125,835,071 | 87.14 | 18,573,338 | 12.86 | 28,278 |
6 | Disapplication of pre-emption rights in specified circumstances | 143,264,607 | 99.19 | 1,172,080 | 0.81 | - |
7 | Disapplication of pre-emption rights in additional circumstances | 119,856,072 | 83.18 | 24,242,889 | 16.82 | 337,726 |
8 | Authorise market purchases of the Company's Ordinary Shares | 143,853,843 | 100 | - | 0 | 582,844 |
9 | Re-issuance of Treasury Shares | 142,676,687 | 98.78 | 1,760,000 | 1.22 | - |
--- ENDS ---
Contact Details
Uniphar Group
| Tel: +353 (0) 1 428 7777 |
Allan Smylie, Head of Strategy and IR | |
| |
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)
| Tel: +353 (0) 1 679 6363 |
Daragh O'Reilly Niall Gilchrist Ivan Murphy |
|
|
|
RBC Capital Markets (Joint Corporate Broker)
| Tel: +44 (0) 20 7653 4000 |
Jamil Miah Rupert Walford |
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
| Tel: +44 (0) 20 7710 7600 |
Matt Blawat Ben Maddison Francis North |
|
|
|
Q4 PR
| Tel: +353 (0) 1 475 1444 |
Iarla Mongey, Public Relations Advisor to Uniphar Group |
|
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
Follow the stocks
